目的:探讨血清β2-微球蛋白(β2-MG)、内脏脂肪素(visfatin)水平变化与老年高血压患者血压变异性(BPV)的关联性。方法:选取某院2021年1月—2022年12月收治的120例老年高血压患者为研究组,同期120例血压正常体检老年人为对照组,根据24 h...目的:探讨血清β2-微球蛋白(β2-MG)、内脏脂肪素(visfatin)水平变化与老年高血压患者血压变异性(BPV)的关联性。方法:选取某院2021年1月—2022年12月收治的120例老年高血压患者为研究组,同期120例血压正常体检老年人为对照组,根据24 h收缩压变异性(24 h SBPV)将研究组分为低BPV(35例,24 h SBPV<15%)、中BPV(47例,24 h SBPV为15%~20%)、高BPV(38例,24 h SBPV>20%)3个亚组。比较2组入院时血清β2-MG、visfatin水平、血压参数,分析入院时血清β2-MG、visfatin水平与血压参数的相关性,比较不同程度BPV患者入院时血清β2-MG、visfatin水平,分析入院时血清β2-MG、visfatin联合检测对老年高血压患者BPV程度的诊断价值。结果:研究组β2-MG[(5.46±1.13)mg/mL]、visfatin[(9.75±2.08)μg/L]水平高于对照组[(1.37±0.42)mg/mL、(2.86±0.61)μg/L],差异具有统计学意义(P<0.05);研究组24 h DBP、24 h SBP、24 h DBPV、24 h SBPV均高于对照组,差异具有统计学意义(P<0.05);入院时血清β2-MG、visfatin水平与24 h DBP、24 h SBP、24 h DBPV、24 h SBPV均呈正相关,差异具有统计学意义(r_(β2-MG)=0.516、0.622、0.439、0.725,r_(visfatin)=0.703、0.681、0.617、0.658)(P<0.05);不同程度BPV患者入院时血清β2-MG、visfatin水平比较:高BPV>中BPV>低BPV,差异具有统计学意义(P<0.05);入院时,血清β2-MG、visfatin联合鉴别诊断高BPV严重程度AUC为0.909,大于单独指标鉴别诊断,差异具有统计学意义(P<0.05)。结论:β2-MG、visfatin水平变化与老年高血压患者血压变异性有密切关联,可作为临床诊断病情的重要参考依据。展开更多
AIM: To investigate the diagnostic utility of beta 2 microglobulin(B2-M) levels and analyze this correlation with the activity of inflammatory bowel disease(IBD).METHODS: Overall, 78 IBD patients and 30 healthy contro...AIM: To investigate the diagnostic utility of beta 2 microglobulin(B2-M) levels and analyze this correlation with the activity of inflammatory bowel disease(IBD).METHODS: Overall, 78 IBD patients and 30 healthy controls were enrolled in the study. We examined B2-M serum levels in 43 ulcerative colitis(UC) patients, 35 with Crohn's disease(CD) and 30 control subjects, using an enzymatic method. Patients were divided into two groups according to two disease types: active and in remission. Subjects were also divided into two subgroups according to extent of the disease: left-side and pancolitis for UC and ileitis and ileocolitis for CD. All groups were compared for mean serum B2-M levels and also examined to see whether there was a correlation between serum B2-M levels and other inflammatory markers.RESULTS: The mean serum B2-M levels in the control group, UC and CD were 1.71, 2.41 and 2.24 respectively. B2-M values ≥ 1.96 mg/L had a 62% sensitivity, 76% specificity, a 79% positive predictive value, and a 58% negative predictive value for UC patients. B2-Mvalues ≥ 1.70 mg/L had 80% sensitivity, 53% specificity, 66% positive predictive value, and 69% negative predictive value for CD patients. Mean B2-M values were significantly higher in ulcerative colitis and Crohn's disease patients than in healthy controls(UC 2.41 ± 0.87 vs 1.71 ± 0.44, P = 0.002; CD 2.24 ± 1.01 vs 1.71 ± 0.44, P = 0.033). Also, mean B2-M values were significantly higher in active disease when compared to patients in remission(UC 2.66 ± 0.92 vs 1.88 ± 0.41, P = 0.004; CD 2.50 ± 1.15 vs 1.73 ± 0.31, P = 0.033). The difference between groups(UC and CD) in terms of serum B2-M levels was statistically insignificant(2.41 ± 0.87 vs 2.24 ± 1.01, P > 0.05 respectively).CONCLUSION: Serum B2-M levels may be used as an activity parameter in IBD.展开更多
The role of beta2-microglobulin(β2M) in dialysisrelated amyloidosis as a specific amyloid precursor was defined in the 1980 s. Studies in those years were largely related to β2M amyloidosis. In 2005, for what was pr...The role of beta2-microglobulin(β2M) in dialysisrelated amyloidosis as a specific amyloid precursor was defined in the 1980 s. Studies in those years were largely related to β2M amyloidosis. In 2005, for what was probably the first time in the available literature, we provided data about the association betweenβ2M and early-onset atherosclerosis in hemodialysis patients without co-morbidities. In recent years, the role of uremic toxins in uremic atherosclerosis and the interest in β2M as a marker of cardiovascular(CV) and/or mortality risk have grown. In the current literature,clinical studies suggest that β2M is an independent, significant predictor of mortality, not only in dialysis patients, but also in predialysis patients and in the highrisk portion of the general population, and it seems to be a factor strongly linked to the presence and severity of CV disease. It is still unknown whether β2M is only a uremic toxin marker or if it also has an active role in vascular damage, but data support that it may reflect an increased burden of systemic atherosclerosis in a setting of underlying chronic kidney disease. Thus, although there have been some inconsistencies among the various analyses relating to β2M, it promises to be a novel risk marker of kidney function in the awareness and detection of high-risk patients. However, more research is required to establish the pathophysiological relationships between retained uremic toxins and further biochemical modifications in the uremic milieu to get answers to the questions of why and how. In this review, the recent literature about the changing role of β2M in uremic patients will be examined.展开更多
Beta-2-microglobulin (B2M) is a low molecular weight polypeptide (11,800 Da) that exists in a free form and a form bound to cell membranes (light chains of HLA class I molecules). Their dosage is used in the explorati...Beta-2-microglobulin (B2M) is a low molecular weight polypeptide (11,800 Da) that exists in a free form and a form bound to cell membranes (light chains of HLA class I molecules). Their dosage is used in the exploration and monitoring of renal function in haemodialysis patients, hence the interest of this study, the objective of which is to study the different players involved in the increase of beta-2-microglobulin. <strong>Materials and Methods:</strong> This was a prospective and descriptive study from January 1<sup>st</sup>, 2017 to August 31, 2017 (08 months). All patients with chronic hemodialysis for 3 years or more were included. We analyzed sociodemographic, clinical and paraclinical data. <strong>Results:</strong> We collected 50 patients. The mean age was 50 ± 4.6 years with extremes of 30 and 82 years. The female sex predominated (52%). Chronic end-stage renal failure was hypertensive (86%), diabetic (4%). All patients benefited from intermittent hemodialysis for 8 hours per week using a low permeability membrane (cuprophane). The average duration of hemodialysis was 68 ± 6.4 months with extremes of 36 and 204 months. Twenty percent (20%) and four percent (4%) of chronic dialysis patients had joint pain and sensory deficit. Phalen’s sign was positive in 2% (1 case), Tinel’s sign in 2% (1 case) and carpal tunnel syndrome in 2% (1 case). The mean serum beta-2-microglobulin level was 58.34 ng/l with extremes of 16.99 and 112.24 ng/l. There was a correlation between hypertensive nephropathies and beta-2-microglobulin levels above 50 ng/l (P < 0.001). The mortality rate was 6%. <strong>Conclusion:</strong> Our study has objectified factors such as inadequate dialysis (8 hours/week), use of low permeability membrane in the increase of beta-2-microglobulin. The increase in serum beta-2-microglobulin levels in our patients is evidence of poor purification of medium molecules. Its reduction can be established by improving the quality of dialysis, in particular by using a high-permeability membrane.展开更多
文摘目的:探讨血清β2-微球蛋白(β2-MG)、内脏脂肪素(visfatin)水平变化与老年高血压患者血压变异性(BPV)的关联性。方法:选取某院2021年1月—2022年12月收治的120例老年高血压患者为研究组,同期120例血压正常体检老年人为对照组,根据24 h收缩压变异性(24 h SBPV)将研究组分为低BPV(35例,24 h SBPV<15%)、中BPV(47例,24 h SBPV为15%~20%)、高BPV(38例,24 h SBPV>20%)3个亚组。比较2组入院时血清β2-MG、visfatin水平、血压参数,分析入院时血清β2-MG、visfatin水平与血压参数的相关性,比较不同程度BPV患者入院时血清β2-MG、visfatin水平,分析入院时血清β2-MG、visfatin联合检测对老年高血压患者BPV程度的诊断价值。结果:研究组β2-MG[(5.46±1.13)mg/mL]、visfatin[(9.75±2.08)μg/L]水平高于对照组[(1.37±0.42)mg/mL、(2.86±0.61)μg/L],差异具有统计学意义(P<0.05);研究组24 h DBP、24 h SBP、24 h DBPV、24 h SBPV均高于对照组,差异具有统计学意义(P<0.05);入院时血清β2-MG、visfatin水平与24 h DBP、24 h SBP、24 h DBPV、24 h SBPV均呈正相关,差异具有统计学意义(r_(β2-MG)=0.516、0.622、0.439、0.725,r_(visfatin)=0.703、0.681、0.617、0.658)(P<0.05);不同程度BPV患者入院时血清β2-MG、visfatin水平比较:高BPV>中BPV>低BPV,差异具有统计学意义(P<0.05);入院时,血清β2-MG、visfatin联合鉴别诊断高BPV严重程度AUC为0.909,大于单独指标鉴别诊断,差异具有统计学意义(P<0.05)。结论:β2-MG、visfatin水平变化与老年高血压患者血压变异性有密切关联,可作为临床诊断病情的重要参考依据。
文摘AIM: To investigate the diagnostic utility of beta 2 microglobulin(B2-M) levels and analyze this correlation with the activity of inflammatory bowel disease(IBD).METHODS: Overall, 78 IBD patients and 30 healthy controls were enrolled in the study. We examined B2-M serum levels in 43 ulcerative colitis(UC) patients, 35 with Crohn's disease(CD) and 30 control subjects, using an enzymatic method. Patients were divided into two groups according to two disease types: active and in remission. Subjects were also divided into two subgroups according to extent of the disease: left-side and pancolitis for UC and ileitis and ileocolitis for CD. All groups were compared for mean serum B2-M levels and also examined to see whether there was a correlation between serum B2-M levels and other inflammatory markers.RESULTS: The mean serum B2-M levels in the control group, UC and CD were 1.71, 2.41 and 2.24 respectively. B2-M values ≥ 1.96 mg/L had a 62% sensitivity, 76% specificity, a 79% positive predictive value, and a 58% negative predictive value for UC patients. B2-Mvalues ≥ 1.70 mg/L had 80% sensitivity, 53% specificity, 66% positive predictive value, and 69% negative predictive value for CD patients. Mean B2-M values were significantly higher in ulcerative colitis and Crohn's disease patients than in healthy controls(UC 2.41 ± 0.87 vs 1.71 ± 0.44, P = 0.002; CD 2.24 ± 1.01 vs 1.71 ± 0.44, P = 0.033). Also, mean B2-M values were significantly higher in active disease when compared to patients in remission(UC 2.66 ± 0.92 vs 1.88 ± 0.41, P = 0.004; CD 2.50 ± 1.15 vs 1.73 ± 0.31, P = 0.033). The difference between groups(UC and CD) in terms of serum B2-M levels was statistically insignificant(2.41 ± 0.87 vs 2.24 ± 1.01, P > 0.05 respectively).CONCLUSION: Serum B2-M levels may be used as an activity parameter in IBD.
文摘The role of beta2-microglobulin(β2M) in dialysisrelated amyloidosis as a specific amyloid precursor was defined in the 1980 s. Studies in those years were largely related to β2M amyloidosis. In 2005, for what was probably the first time in the available literature, we provided data about the association betweenβ2M and early-onset atherosclerosis in hemodialysis patients without co-morbidities. In recent years, the role of uremic toxins in uremic atherosclerosis and the interest in β2M as a marker of cardiovascular(CV) and/or mortality risk have grown. In the current literature,clinical studies suggest that β2M is an independent, significant predictor of mortality, not only in dialysis patients, but also in predialysis patients and in the highrisk portion of the general population, and it seems to be a factor strongly linked to the presence and severity of CV disease. It is still unknown whether β2M is only a uremic toxin marker or if it also has an active role in vascular damage, but data support that it may reflect an increased burden of systemic atherosclerosis in a setting of underlying chronic kidney disease. Thus, although there have been some inconsistencies among the various analyses relating to β2M, it promises to be a novel risk marker of kidney function in the awareness and detection of high-risk patients. However, more research is required to establish the pathophysiological relationships between retained uremic toxins and further biochemical modifications in the uremic milieu to get answers to the questions of why and how. In this review, the recent literature about the changing role of β2M in uremic patients will be examined.
文摘Beta-2-microglobulin (B2M) is a low molecular weight polypeptide (11,800 Da) that exists in a free form and a form bound to cell membranes (light chains of HLA class I molecules). Their dosage is used in the exploration and monitoring of renal function in haemodialysis patients, hence the interest of this study, the objective of which is to study the different players involved in the increase of beta-2-microglobulin. <strong>Materials and Methods:</strong> This was a prospective and descriptive study from January 1<sup>st</sup>, 2017 to August 31, 2017 (08 months). All patients with chronic hemodialysis for 3 years or more were included. We analyzed sociodemographic, clinical and paraclinical data. <strong>Results:</strong> We collected 50 patients. The mean age was 50 ± 4.6 years with extremes of 30 and 82 years. The female sex predominated (52%). Chronic end-stage renal failure was hypertensive (86%), diabetic (4%). All patients benefited from intermittent hemodialysis for 8 hours per week using a low permeability membrane (cuprophane). The average duration of hemodialysis was 68 ± 6.4 months with extremes of 36 and 204 months. Twenty percent (20%) and four percent (4%) of chronic dialysis patients had joint pain and sensory deficit. Phalen’s sign was positive in 2% (1 case), Tinel’s sign in 2% (1 case) and carpal tunnel syndrome in 2% (1 case). The mean serum beta-2-microglobulin level was 58.34 ng/l with extremes of 16.99 and 112.24 ng/l. There was a correlation between hypertensive nephropathies and beta-2-microglobulin levels above 50 ng/l (P < 0.001). The mortality rate was 6%. <strong>Conclusion:</strong> Our study has objectified factors such as inadequate dialysis (8 hours/week), use of low permeability membrane in the increase of beta-2-microglobulin. The increase in serum beta-2-microglobulin levels in our patients is evidence of poor purification of medium molecules. Its reduction can be established by improving the quality of dialysis, in particular by using a high-permeability membrane.
